title: Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors.
abstract: BACKGROUND
  Little is known about the role of the CD56+ natural killer (NK) cell dose on the outcome of allogeneic peripheral blood stem cell transplantation (PBSCT). Recently, higher dose of NK cells has been associated with a lower incidence of severe graft-versus-host disease (GVHD). The current study attempted to evaluate the effect of the NK cell dose on transplant outcomes in allogeneic PBSCT setting.
  
  
  METHODS
  Sixty-one cytokine mobilized PBSC recipients were analyzed according to the infused dose of CD34+ cells and NK cells in relation to overall survival (OS), non-relapse mortality (NRM), GVHD, and infectious events.
  
  
  RESULTS
  The group received a higher dose of NK cells (> or =5 x 10(7)/kg) showed a lower incidence of NRM (P = 0.0186) and infectious events (P = 0.0107). In a multivariate analysis, a higher dose of NK cells was correlated to better transplant outcomes for NRM (P = 0.042) with CD34+ cell dose (P = 0.018), and for infectious events (P = 0.013) with CD34+ cell dose (P = 0.016). Higher NK cell infusion group also showed a faster immune recovery in serial measurements at days +90, +180, and +365.
  
  
  CONCLUSIONS
  High dose of NK cells may play an important role in improving transplant outcomes, in terms of reducing NRM and infectious events together with CD34+ cells.
authors.affiliation: Department of Hematology/Oncology, Kyungpook National University Hospital, 50 Samduk 2-ga, Jung-Gu, Daegu 700-721, Korea.
authors.forename: Dong Hwan
authors.initials: DH
authors.lastname: Kim
authors.forename: Sang Kyun
authors.initials: SK
authors.lastname: Sohn
authors.forename: Nan Young
authors.initials: NY
authors.lastname: Lee
authors.forename: Jin Ho
authors.initials: JH
authors.lastname: Baek
authors.forename: Jong Gwang
authors.initials: JG
authors.lastname: Kim
authors.forename: Dong Il
authors.initials: DI
authors.lastname: Won
authors.forename: Jang Soo
authors.initials: JS
authors.lastname: Suh
authors.forename: Kyu Bo
authors.initials: KB
authors.lastname: Lee
authors.forename: Im Hee
authors.initials: IH
authors.lastname: Shin
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34; D002452:Cell Count; D005260:Female; D006086:Graft vs Host Disease; D006650:Histocompatibility Testing; D006801:Humans; D007107:Immune System / Q000502:physiology; D015994:Incidence; D007239:Infections / Q000209:etiology*; D007694:Killer Cells, Natural / Q000637:transplantation*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods* / Q000401:mortality / Q000592:standards; D012038:Regeneration; D012189:Retrospective Studies; D035781:Siblings; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34